Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
RELATED PRODUCTS
-
AV45 (R+D)
AV45 (R+D)It is indicated for estimating the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test. -
PYROPHOSPHATE
PYROPHOSPHATEIt is indicated for performing bone scintigraphy, detection of cardiac pathologies and "in vivo" and "in vitro" marking of erythrocytes. 1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to... -
177Lu DOTATATE (I+D)
177Lu DOTATATE (I+D)It is a radiolabeled somatostatin analog indicated for: - The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut...

